Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication SYMBRAVO is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use SYMBRAVO should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with SYMBRAVO, the diagnosis of migraine should be reconsidered before SYMBRAVO is administered to treat any subsequent attacks. FDA label
Meloxicam · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Meloxicam Tablets 15 mg |
| 2 | ACTIVE_COMPARATOR | Mobic® Tablets 15 mg |
| Name | Type | Description |
|---|---|---|
| Meloxicam Tablets 15 mg | DRUG | 15mg, single dose fasting |
| Mobic® Tablets 15 mg | DRUG | 15mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administrati...
Meloxicam is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is also known as Meloxicam Tablets 15 mg. The specific therapeutic indication for this asset is undisclosed, and it falls under the therapeutic area classified as Other. It is currently in Phase 1 clinical development.
Meloxicam targets PTGS2, also known as cyclooxygenase-2. It acts as an inhibitor of this enzyme. PTGS2 is involved in the inflammatory response, and inhibiting it is the mechanism by which this small molecule exerts its pharmacological activity.
Meloxicam is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the clinical development of Meloxicam Tablets 15 mg. The drug is a small molecule currently in Phase 1 testing.
Meloxicam is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, with no active trials currently ongoing. The completed trials enrolled a total of 57 participants.
Meloxicam has been studied in two completed Phase 1 trials. NCT00649675 was a food study of Meloxicam Tablets 15 mg versus Mobic Tablets 15 mg, enrolling 27 healthy volunteers. NCT00649077 was a fasting study of the same comparison, enrolling 30 healthy volunteers. Both trials were conducted in the United States.